Leland Gershell
Stock Analyst at Oppenheimer
(4.24)
# 283
Out of 4,829 analysts
129
Total ratings
39.83%
Success rate
20.17%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $7 | $4.95 | +41.41% | 2 | May 9, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $704 → $708 | $560.90 | +26.23% | 7 | May 9, 2025 | |
| QNCX Quince Therapeutics | Initiates: Outperform | $10 | $1.03 | +870.87% | 1 | Mar 24, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $12 → $20 | $6.70 | +198.51% | 3 | Mar 11, 2025 | |
| BMRN BioMarin Pharmaceutical | Upgrades: Outperform | $98 | $61.37 | +59.69% | 3 | Feb 24, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $58.97 | +28.89% | 1 | Dec 20, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $154.43 | +16.56% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $20.08 | +158.96% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $106.38 | +38.18% | 2 | Nov 8, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $5 | $0.52 | +859.69% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.70 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $73 | $76.70 | -4.82% | 8 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $11.14 | +259.07% | 9 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $14.55 | +264.26% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $35.68 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $7.11 | +504.78% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $2.97 | +910.10% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.98 | +506.06% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $0.04 | +62,400.00% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $13.12 | +113.41% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.27 | +664.53% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $33.32 | +119.09% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $2.01 | +895.02% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $23.83 | +21.70% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $4.00 | +775.00% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.75 | +1,231.56% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.29 | +1,450.39% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $270.19 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.20 | +983.33% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $3.34 | +3,492.81% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.72 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $0.91 | +39,586,440.58% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $17.96 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.89 | +2,544.94% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $10.42 | - | 5 | Mar 31, 2020 |
Xeris Biopharma Holdings
May 9, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $4.95
Upside: +41.41%
argenx SE
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $560.90
Upside: +26.23%
Quince Therapeutics
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.03
Upside: +870.87%
Trevi Therapeutics
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $6.70
Upside: +198.51%
BioMarin Pharmaceutical
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $61.37
Upside: +59.69%
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $58.97
Upside: +28.89%
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $154.43
Upside: +16.56%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $20.08
Upside: +158.96%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $106.38
Upside: +38.18%
Veru Inc.
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.52
Upside: +859.69%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.70
Upside: -
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $76.70
Upside: -4.82%
Oct 16, 2024
Reiterates: Outperform
Price Target: $40
Current: $11.14
Upside: +259.07%
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $14.55
Upside: +264.26%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $35.68
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $7.11
Upside: +504.78%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $2.97
Upside: +910.10%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.98
Upside: +506.06%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $0.04
Upside: +62,400.00%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $13.12
Upside: +113.41%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.27
Upside: +664.53%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $33.32
Upside: +119.09%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $2.01
Upside: +895.02%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $23.83
Upside: +21.70%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $4.00
Upside: +775.00%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.75
Upside: +1,231.56%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.29
Upside: +1,450.39%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $270.19
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.20
Upside: +983.33%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $3.34
Upside: +3,492.81%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.72
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $0.91
Upside: +39,586,440.58%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $17.96
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.89
Upside: +2,544.94%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $10.42
Upside: -